Cervical Anterior Articles & Analysis
6 news found
Raymond Yip led training sessions on the CP-ESP cervical prosthesis. The first session took place in July with a Malaysian surgeon, followed by a second session in mid-October, with two other surgeons, also from Malaysia. ...
” i-FACTOR bone graft has over 10 years of clinical success in Europe and was approved in the U.S. for use in anterior cervical discectomy and fusion (ACDF) procedures in 2015. The drug-device combination product is based on small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease. ...
i-FACTOR bone graft has over 10 years of clinical success in Europe and was approved in the U.S. for use in anterior cervical discectomy and fusion (ACDF) procedures in 2015. The drug-device combination product is based on small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease. ...
Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures. “In addition to the commercial launch in Canada, the latest i-FACTOR+ MATRIX generation is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced. i-FACTOR+ ...
Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures. In 2018, the company enrolled the first patients in an IDE clinical trial, ASPIRE, evaluating the safety and efficacy of its next-generation product, P-15L Peptide Enhanced Bone Graft, for use in patients undergoing ...
Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. ...